Beta-blockers for hemangiomas

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Infantile hemangioma (IH) is the most common tumor of infancy ranging from a tiny red papule to a giant mass. Its typical natural history is characterized by an early rapid growth following birth and a slow spontaneous involution which is complete before puberty but almost complete within the first 3-6 years of life. The cause underlying IH is still unknown, but the role of fetal hypoxic stress is strongly suggested as a triggering signal. A different hypothesis suggests that IH can be derived from embolized placental progenitor cells that lodge in privileged sites of the developing embryo. Alternatively, IH has been reported as an aberrant proliferation and differentiation of a primitive mesoderm-derived hemogenic endothelium regulated by the renin-angiotensin system (RAS) leading to propose angiotensin-converting enzyme (ACE) as a potential therapeutic target. While some angiogenic factors have been identified (e.g., mast cells, heparin), there are no data demonstrating a hereditary component. Immunohistochemical studies of IH confirm their vascular origin. During the proliferative phase, IH shows a high expression of cell proliferation nuclear antigen, vascular endothelial growth factor (VEGF), type IV collagen, urokinase, basic fibroblast growth factor (bFGF), and von Willebrand factor. These data demonstrate active angiogenesis and are not observed in vascular malformations.

Original languageEnglish
Title of host publicationEuropean Handbook of Dermatological Treatments, Third Edition
PublisherSpringer Berlin Heidelberg
Pages1393-1402
Number of pages10
ISBN (Print)9783662451397, 9783662451380
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Hemangioma
Hemangioblasts
Nuclear Antigens
Vascular Malformations
Collagen Type IV
Angiogenesis Inducing Agents
Urokinase-Type Plasminogen Activator
von Willebrand Factor
Fibroblast Growth Factor 2
Mesoderm
Peptidyl-Dipeptidase A
Puberty
Renin-Angiotensin System
Natural History
Mast Cells
Vascular Endothelial Growth Factor A
Blood Vessels
Heparin
Stem Cells
Embryonic Structures

Keywords

  • Beta-blockers
  • Hemangioma
  • Oral steroids
  • Propranolol
  • Side effects
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gelmetti, C., & Cavalli, R. (2015). Beta-blockers for hemangiomas. In European Handbook of Dermatological Treatments, Third Edition (pp. 1393-1402). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_135

Beta-blockers for hemangiomas. / Gelmetti, Carlo; Cavalli, Riccardo.

European Handbook of Dermatological Treatments, Third Edition. Springer Berlin Heidelberg, 2015. p. 1393-1402.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gelmetti, C & Cavalli, R 2015, Beta-blockers for hemangiomas. in European Handbook of Dermatological Treatments, Third Edition. Springer Berlin Heidelberg, pp. 1393-1402. https://doi.org/10.1007/978-3-662-45139-7_135
Gelmetti C, Cavalli R. Beta-blockers for hemangiomas. In European Handbook of Dermatological Treatments, Third Edition. Springer Berlin Heidelberg. 2015. p. 1393-1402 https://doi.org/10.1007/978-3-662-45139-7_135
Gelmetti, Carlo ; Cavalli, Riccardo. / Beta-blockers for hemangiomas. European Handbook of Dermatological Treatments, Third Edition. Springer Berlin Heidelberg, 2015. pp. 1393-1402
@inbook{1c0f4634d6ad4e9fbcf5404eabef674d,
title = "Beta-blockers for hemangiomas",
abstract = "Infantile hemangioma (IH) is the most common tumor of infancy ranging from a tiny red papule to a giant mass. Its typical natural history is characterized by an early rapid growth following birth and a slow spontaneous involution which is complete before puberty but almost complete within the first 3-6 years of life. The cause underlying IH is still unknown, but the role of fetal hypoxic stress is strongly suggested as a triggering signal. A different hypothesis suggests that IH can be derived from embolized placental progenitor cells that lodge in privileged sites of the developing embryo. Alternatively, IH has been reported as an aberrant proliferation and differentiation of a primitive mesoderm-derived hemogenic endothelium regulated by the renin-angiotensin system (RAS) leading to propose angiotensin-converting enzyme (ACE) as a potential therapeutic target. While some angiogenic factors have been identified (e.g., mast cells, heparin), there are no data demonstrating a hereditary component. Immunohistochemical studies of IH confirm their vascular origin. During the proliferative phase, IH shows a high expression of cell proliferation nuclear antigen, vascular endothelial growth factor (VEGF), type IV collagen, urokinase, basic fibroblast growth factor (bFGF), and von Willebrand factor. These data demonstrate active angiogenesis and are not observed in vascular malformations.",
keywords = "Beta-blockers, Hemangioma, Oral steroids, Propranolol, Side effects, Treatment",
author = "Carlo Gelmetti and Riccardo Cavalli",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-662-45139-7_135",
language = "English",
isbn = "9783662451397",
pages = "1393--1402",
booktitle = "European Handbook of Dermatological Treatments, Third Edition",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Beta-blockers for hemangiomas

AU - Gelmetti, Carlo

AU - Cavalli, Riccardo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Infantile hemangioma (IH) is the most common tumor of infancy ranging from a tiny red papule to a giant mass. Its typical natural history is characterized by an early rapid growth following birth and a slow spontaneous involution which is complete before puberty but almost complete within the first 3-6 years of life. The cause underlying IH is still unknown, but the role of fetal hypoxic stress is strongly suggested as a triggering signal. A different hypothesis suggests that IH can be derived from embolized placental progenitor cells that lodge in privileged sites of the developing embryo. Alternatively, IH has been reported as an aberrant proliferation and differentiation of a primitive mesoderm-derived hemogenic endothelium regulated by the renin-angiotensin system (RAS) leading to propose angiotensin-converting enzyme (ACE) as a potential therapeutic target. While some angiogenic factors have been identified (e.g., mast cells, heparin), there are no data demonstrating a hereditary component. Immunohistochemical studies of IH confirm their vascular origin. During the proliferative phase, IH shows a high expression of cell proliferation nuclear antigen, vascular endothelial growth factor (VEGF), type IV collagen, urokinase, basic fibroblast growth factor (bFGF), and von Willebrand factor. These data demonstrate active angiogenesis and are not observed in vascular malformations.

AB - Infantile hemangioma (IH) is the most common tumor of infancy ranging from a tiny red papule to a giant mass. Its typical natural history is characterized by an early rapid growth following birth and a slow spontaneous involution which is complete before puberty but almost complete within the first 3-6 years of life. The cause underlying IH is still unknown, but the role of fetal hypoxic stress is strongly suggested as a triggering signal. A different hypothesis suggests that IH can be derived from embolized placental progenitor cells that lodge in privileged sites of the developing embryo. Alternatively, IH has been reported as an aberrant proliferation and differentiation of a primitive mesoderm-derived hemogenic endothelium regulated by the renin-angiotensin system (RAS) leading to propose angiotensin-converting enzyme (ACE) as a potential therapeutic target. While some angiogenic factors have been identified (e.g., mast cells, heparin), there are no data demonstrating a hereditary component. Immunohistochemical studies of IH confirm their vascular origin. During the proliferative phase, IH shows a high expression of cell proliferation nuclear antigen, vascular endothelial growth factor (VEGF), type IV collagen, urokinase, basic fibroblast growth factor (bFGF), and von Willebrand factor. These data demonstrate active angiogenesis and are not observed in vascular malformations.

KW - Beta-blockers

KW - Hemangioma

KW - Oral steroids

KW - Propranolol

KW - Side effects

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84944548183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944548183&partnerID=8YFLogxK

U2 - 10.1007/978-3-662-45139-7_135

DO - 10.1007/978-3-662-45139-7_135

M3 - Chapter

AN - SCOPUS:84944548183

SN - 9783662451397

SN - 9783662451380

SP - 1393

EP - 1402

BT - European Handbook of Dermatological Treatments, Third Edition

PB - Springer Berlin Heidelberg

ER -